Preventing recurrent venous thromboembolism
Someone who has had a first episode of venous thromboembolism (VTE) is about 40 times more likely to have an episode in the future than a person who has never experienced such an event.1 Prolonged use of anticoagulation therapy reduces this likelihood of recurrence, but comes with a risk of bleeding. Guidelines cite certain medical conditions that increase the risk of recurrence of VTE (such as cancer and inflammatory bowel disease)2 but, beyond that, there are no reliable tools for stratifying individual patients who are at higher risk of recurrence. Here we review the evidence regarding risk factors for recurrence that might influence the decision to recommend prolonged anticoagulant therapy after a first episode of VTE, and we consider the implications for practice.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
(2009). Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban. DTB
47: 116-120
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Cardiovascular Medicine
-
Gastrointestinal system
-
Cardiovascular system
-
Haematology (drugs and medicines)
- Gastroenterology
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
